Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension

This article was originally published here

“We’re pleased that the FDA has granted this designation for sotatercept,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron. “In preclinical studies,

The post Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply